NEK2 and cholangiocarcinoma: In addition, overexpression of NEK2 has been demonstrated in many tumors and associated with aggressive cancer phenotype and poor prognosis in pancreatic ductal adenocarcinoma, colorectal carcinoma, cholangiocarcinoma, and breast cancer.